Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript
Vertex Pharmaceuticals Incorporated ( VRTX ) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Conference Call Participants James A. Tumlin Richard Lafayette Brad Rovin Carter Gould - Cantor Fitzgerald & Co., Research Division Adam Ferrari - JPMorgan Chase & Co, Research Division Sadia Rahman - Wells Fargo Securities, LLC, Research Division Ananda Ghosh - H.C.
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge.
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.8 per share, beating the Zacks Consensus Estimate of $4.55 per share. This compares to earnings of $4.38 per share a year ago.
Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Stuart Arbuckle Charles Wagner - Executive VP, COO & CFO Duncan J. McKechnie - Chief Commercial Officer, Head of North America Commercial & Executive VP Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Evan Seigerman - BMO Capital Markets Equity Research Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Terence Flynn Philip Nadeau - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division William Pickering - Sanford C.
My Top Growth Stock to Buy in November
Vertex Pharmaceuticals has three key ways to deliver strong growth. Two factors about the biotech company are especially comforting.
Exploring Analyst Estimates for Vertex (VRTX) Q3 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Here's Why Vertex Pharmaceuticals (VRTX) Fell More Than Broader Market
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $414.86, representing a -1.49% change from its previous close.
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $403.3, indicating a -1.36% shift from the previous trading day.
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $408.85, representing a +1.15% change from its previous close.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.
